Skip to main content
SpringerLink
Log in

Chemotherapy

  • Chapter
Pediatric CNS Tumors

Part of the book series: Pediatric Oncology ((PEDIATRICO))

Abstract

Chemotherapy treatment goals for pediatric brain tumors reflect the extreme heterogeneity of this group of malignancies. In the setting of average-risk medulloblastoma and germinoma, which have high cure rates with radiation treatment alone, chemotherapy is used to reduce radiation doses, yet maintain high cure rates. For infants with malignant brain tumors who are particularly vulnerable to radiation-related morbidity, chemotherapy has been used to delay or defer radiation treatment. Similarly, in the setting of unresectable, low-grade astrocytoma, chemotherapy can provide prolonged disease stabilization, perhaps allowing for delay or deferral of radiation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alama AB, Cagnoli F, Schettini G (1997) Antisense oligonucle- otides as therapeutic agents. Pharmacol Res 36: 171–178

    Article  PubMed  CAS  Google Scholar 

  2. Allen JC, Gosl G, Walker R (1985) Chemotherapy trials in recurrent primary intracranial germ cell tumors. J Neurooncol 3: 147–152

    Article  PubMed  CAS  Google Scholar 

  3. Aoki K,Yoshida T, Matsumoto N et al (1997) Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog 20: 251–258

    Article  PubMed  CAS  Google Scholar 

  4. Ashley DM, Meier L, Kerby T et al (1996) Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14: 1922–1927

    PubMed  CAS  Google Scholar 

  5. Ater JL, Van Eys J, Woo SY et al (1997) MOPP chemotherapy without irradiation as a primary postsurgical therapy for brain tumors in infants and young children. J Neurooncology 32: 243–252

    Article  CAS  Google Scholar 

  6. Balis FM, Holcenberg JS, Blaney S (2000) General principles of chemotherapy. In: Pizzo PA (ed, Polack DG) Principles and practice of pediatric oncology. Lippincott, Williams and Wilkins, Philadelphia, pp 237–308

    Google Scholar 

  7. Barba D, Saris SC, Holder C et al (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175–182

    Article  PubMed  CAS  Google Scholar 

  8. Bashir R, Hochberg FH, Linggood RM et al (1988) Preirradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. J Neurosurg 68: 917

    Article  PubMed  CAS  Google Scholar 

  9. Bertolone SJ, Baum ES, Krivit W, Hammond GD (1989) A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Children’s Cancer Study Group. J Neurooncol 7: 5–11

    Google Scholar 

  10. Bicknell R, Harris AL (1996) Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 8: 60–65

    Article  PubMed  CAS  Google Scholar 

  11. Bigner DD, Brown MT, Friedman AH et al (1998) Iodine-131–1abeled anti-tenascin monoclonal antibody 8106 treatment of patients with recurrent malignant glioma. J Cl in Oncol

    Google Scholar 

  12. -2212

    Google Scholar 

  13. Bloom HJ, Peckham MJ, Richardson AE et al (1973) Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. BY J Cancer 27: 253–267

    Article  CAS  Google Scholar 

  14. Bobo RH, Laske DW, Akbasak A et al (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91: 2076–208o

    Google Scholar 

  15. Bouffet E, Foreman N (1999) Chemotherapy for intracranial ependymomas. Childs Nery Syst 15: 563–570

    Article  CAS  Google Scholar 

  16. Bouffet E, Khelfaoui F, Philip I et al (1997) High dose carmustine for high grade gliomas in childhood. Cancer Chemother Pharmacol 39: 376–379

    Article  PubMed  CAS  Google Scholar 

  17. Bouffet E, Raquin M, Doz F et al (moo) Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 88: 685–692

    Google Scholar 

  18. Brem H, Piantadosi S, Burger PC (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor treatment group. Lancet 345: 1008–1012

    Google Scholar 

  19. Burger P, Komenar I, Schold S (1981) Encephalomyelopathy following high-dose BCNU therapy. Cancer 48: 1318

    Article  Google Scholar 

  20. Busca A, Miniero R, Besenzon L et al (1997) Etoposide-containing regimens with autologous bone marrow transplantation in children with malignant brain tumors. Childs Nery Syst 13: 572–577

    Article  CAS  Google Scholar 

  21. Byrne J, Mulvihill JJ, Myers MH et al (1987) Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 317: 1315–1321

    Article  PubMed  CAS  Google Scholar 

  22. Chamberlain M (2001) Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatr Neurol 24: 117–121

    Article  PubMed  CAS  Google Scholar 

  23. Chamberlain MC, Kormanik PA (1997) Chronic oral VP-16 for recurrent medulloblastoma. Pediatr Neurol 17: 230–234

    Article  PubMed  CAS  Google Scholar 

  24. Chang SM, Kuhn JG, Robins HI et al (1999) Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17:984-990

    Google Scholar 

  25. Chauncey T (2001) Drug resistance mechanisms in acute leukemia. Curr Opin Oncol 13: 21–26

    Article  PubMed  CAS  Google Scholar 

  26. Cheney IW, Johnson DE, Vaillancourt MT et al (1998) Suppression of tumorigenicity of glioblastoma cells by adenovirusmediated MMC1/PTEN gene transfer. Cancer Res 58:23312334

    Google Scholar 

  27. Chou PM, Barquin N, Gonzalez-Crussi F et al (1996) Ependymomas in children express the multidrug resistance gene: immunohistochemical and molecular biologic study. Pediatr Pathol Lab Med 16: 551–561

    Article  PubMed  CAS  Google Scholar 

  28. Chou PM, Reyes-Mugica M, Barquin N et al (1995) Multidrug resistance gene expression in childhood medulloblasotma: correlation with clinical outcome and DNA ploidy in 29 patients. Pediatr Neurosurg 23: 291–292

    Article  Google Scholar 

  29. Cogen PH, McDonald JD (1996) Tumor suppressor genes and medulloblasotma. J Neurooncol 29: 103–112

    Article  PubMed  CAS  Google Scholar 

  30. Culver KW, Ram Z, Wallbridge S et al (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256x550–1552

    Google Scholar 

  31. D’Amato R (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085

    Article  PubMed  Google Scholar 

  32. Dean RL,Emerich DF, Hasler BP et al (1999) Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neurooncology 1: 268–274

    Google Scholar 

  33. Debinski W, Gibo DM, Hulet SW et al (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high grade gliomas. Clin Cancer Res 5: 985–990

    PubMed  CAS  Google Scholar 

  34. Decleves X, Fajac A, Lehmann-Che J et al (2002) Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 98: 173–180

    Article  PubMed  CAS  Google Scholar 

  35. Drevs J, Laus C, Medinger M et al (2002) Antiangiogenesis: current clinical data and future perspectives. Onkologie 25: 520–527

    Article  PubMed  CAS  Google Scholar 

  36. Duffner PK, Horowitz ME, Krischer JP et al (1993) Postoperative chemotherapy and delayed irradiation in children less than three years of age with malignant brain tumors. N Engl J Med 328: 1725–1731

    Google Scholar 

  37. Duffner PK, Horowitz ME, Krischer JP et al (1999) The treatment of malignant brain tumor in infants and very young children: an update of the Pediatric Oncology Group experience. Neurooncology 1: 152–161

    CAS  Google Scholar 

  38. Duffner PK, Krischer JP, Horowitz ME et al (1998) Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group Study. Ann Neurol 44:313–316

    Google Scholar 

  39. Dufful SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33: 161–183

    Article  Google Scholar 

  40. Dunkel IJ, Finlay JL (2002) High-dose chemotherapy with autologous stem cell rescue for brain tumors. Grit Rev Oncol Hematol 41: 197–204

    Article  Google Scholar 

  41. Dunkel IJ, Boyett JM, Yates A, et al (1998a) High-dose carbolatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children’s Cancer Group. J Clin Oncol 16: 222–228

    Google Scholar 

  42. Dunkel IJ, Boyett JM, Yates A et al (1998b) High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children’s Cancer Group. J Neurooncol 37: 67–73

    Google Scholar 

  43. Eilber F, Giuliano A, Eckardt J et al (1987) Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5: 21–26

    PubMed  CAS  Google Scholar 

  44. Einhorn L (1991) Daily oral etoposide in the treatment of cancer. Semin Oncol 18 [Suppl 21:42–47

    Google Scholar 

  45. Fine HA, Figg WD, Jaeckle K et al (2000) Phase Il trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708–715

    PubMed  CAS  Google Scholar 

  46. Finlay JL, Boyett JM, Yates AJ et al (1995) Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine and prednisone with the eight-drugsin-one-day regimen. J Clin Oncol 13: 112–123

    PubMed  CAS  Google Scholar 

  47. Finlay JI,, Goldman S, Wong MC et al (1996) Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children’s Cancer Group. J Clin Oncol 14: 24952503

    Google Scholar 

  48. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186

    Article  PubMed  CAS  Google Scholar 

  49. Friedman HS, Mahaley MS, Schold SC et al (1986) Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurgery 18:335–340

    Google Scholar 

  50. Friedman HS, Kokkinakis DM, Pluda J et al (1998) Phase I trial of 06-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16: 3570–3575

    PubMed  CAS  Google Scholar 

  51. Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 25852597

    Google Scholar 

  52. Fulton D, Urtasun R, Forsyth P (1996) Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27: 149–155

    Article  PubMed  CAS  Google Scholar 

  53. Gaynon PS, Ettinger LJ, Baum, ES et al (1990) Carboplatin in childhood brain tumors. A Children’s Cancer Study Group Phase II trial. Cancer 66:2465–2469

    Google Scholar 

  54. Geyer JR, Zeltzer PM, Boyett JM et al (1994) Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Children’s Cancer Group. J Clin Oncol 12: 1607–1615

    PubMed  CAS  Google Scholar 

  55. Glade-Bender J, Kandel JJ, Yamashiro DJ (2003) VEGF blocking therapy in the treatment of cancer. Exp Opin Biol Ther 3: 236–276

    Article  Google Scholar 

  56. Graham ML, Herndon JE 2nd, Casey JR et al (1997) High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 15: 1814–1823

    PubMed  CAS  Google Scholar 

  57. Grovas AC, Boyett JM, Lindsley K et al (1999) Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children’s Cancer Group. Med Pediatr Oncol 33:83-87

    Google Scholar 

  58. Gururangan S, Dunkel IF, Goldman S et al (1998) Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 16: 2486–2493

    Google Scholar 

  59. Hande K (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34a514–1521

    Google Scholar 

  60. Heideman RL, Douglass EC, Krance RA et al (1993) High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas. J Clin Oncol 11:1458–1465

    Google Scholar 

  61. Hochberg FH, Parker LM, Takvorian T (1981) High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg 54: 455–460

    Article  PubMed  CAS  Google Scholar 

  62. Hongeng S, Brent TP, Sanford RA et al (1997) 06-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clin Cancer Res 3: 2459–2463

    Google Scholar 

  63. Hsiao M, Tse V, Carmel J et al (1997) Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long term survival. Biochem Biophys Res Commun 233:359364

    Google Scholar 

  64. Iwasaki K, Rogers LR, Estes ML et al (1993) Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-a and/or interferon-g. Neurosurgery 33: 489–494

    Google Scholar 

  65. Jaeckle KA, Eyre HJ, Townsend JJ et al (1998) Correlation of tumor O°-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bischoloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16:3310–3315

    Google Scholar 

  66. Jaeckle KA, Hess KR, Yung WK et al (2003) Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21: 2305–2311

    Article  PubMed  CAS  Google Scholar 

  67. Joki T, Heese O, Nikas DC et al (2000) Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibiter, HS-398. Cancer Res 60: 4926

    PubMed  CAS  Google Scholar 

  68. Jordan M (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti Cancer Agents 2: 1–17

    Article  CAS  Google Scholar 

  69. Jorg TH, Hans-Peter L (2003) Expert opinion on pharmacotherapy. Toxicity Platinum Compounds 4: 889–901

    Google Scholar 

  70. Kellie SJ, Barbaric D, Koopmans P et al (2002) Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer 94: 1815–1820

    Article  PubMed  CAS  Google Scholar 

  71. Kenyon BM, Browne F, D’Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971–978

    Google Scholar 

  72. Klement G, Baruchel S, Rak J et al (2000) Continuous low dose therapy with vinblastine and VEGF receptor 2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: 15–24

    Article  Google Scholar 

  73. Kobrinsky N, Packer RJ, Boyett JM et al (1999) Etoposide with or without mannitol for the treatment of recurrent of primarily unresponsive brain tumors: a Children’s Cancer Group Study. J Neurooncol 45:47-54

    Google Scholar 

  74. Koga H, Zhang S, Kumanishi T et al (1994) Analysis of P53 mutations in low-and high-grade astrocytomas by polymerase chain reaction assisted single strand conformation polymorphism and immunohistochemistry. Acta Neuropathol (Berl) 83: 225–232

    Google Scholar 

  75. Kokunai T, Kawamura A, Tamaki N (1997) Induction of differentiation by wild-type p53 gene in a human glioma cell line. J Neurooncol 32: 125–133

    Article  PubMed  CAS  Google Scholar 

  76. Kondo S, Yin D, Takeuchi Jet a1 (1994) Tumor necrosis factor-a induces an increase in susceptibility of human glioblastoma U87MG cells to natural killer cell-mediated lysis. Br J Cancer 69: 627–632

    Article  PubMed  CAS  Google Scholar 

  77. Kortmann RD, Kuhl J, Timmermann B et al (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT’91. Int J Radiat Oncol Biol 46: 269–279

    Article  CAS  Google Scholar 

  78. Kushner BK, Cheung NK (1999) Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol 17: 3221–3225

    Google Scholar 

  79. Lang FF, Bruner JM, Fuller GN et al (2003) Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21: 2508–2518

    Article  PubMed  CAS  Google Scholar 

  80. Lapena P, Isasi C, Vaquero J et al (1991) Modulation by interferon-a of the decreased natural killer activity in patients with glioblastoma. Acta Neurochir (Wein) 109: 109–113

    Article  CAS  Google Scholar 

  81. Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors. Nature Med 12: 13621368

    Google Scholar 

  82. Levin VA, Lamborn K, Wara Wet al (2000) Phase II study of 6thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children. Neurooncology 2: 22–28

    CAS  Google Scholar 

  83. Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947

    Article  PubMed  CAS  Google Scholar 

  84. Li Y, Millikan RC, Carozza Set al (1998) p53 mutations in malignant gliomas. Cancer Epidemiol Biomarkers Prey 7: 303–308

    Google Scholar 

  85. Lillehei KO, Mitchell DH, Johnson SD et al (1991) Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28: 16–23

    Article  PubMed  CAS  Google Scholar 

  86. Link MP, Goorin AM, Miser AW et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 16001606

    Google Scholar 

  87. Longee DC, Friedman HS, Albright RE Jr et al (1990) Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurooncol 72:583–588

    Google Scholar 

  88. Mahaley MS, Bigner DD, Dudka LF et al (1983) Immunobiology of primary intracranial tumors, part 7. Active immunization of patients with anaplastic human glioma cells: a pilot study. J Neurosurg 59: 201–207

    Article  PubMed  Google Scholar 

  89. Mahaley MS Jr, Hipp SW, Dropcho EJ et al (1989) Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 70:371

    Google Scholar 

  90. Mahoney DH Jr, Strother D, Camitta B et al (1996) High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot Pediatric Oncology Group study. J Clin Oncol 14: 382–388

    PubMed  CAS  Google Scholar 

  91. Mahoney DH Jr, Cohen ME, Friedman HS et al (2000) Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neurooncology 2: 213–230

    Google Scholar 

  92. Mamot C, Drummond DC, Greiser U et al (2003) Epidermal Growth Factor Receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFRand EGFRvIII-overexpressing tumor cells. Cancer Res 63: 3154–3161

    Google Scholar 

  93. Mason WP, Goldman S, Yates A) et al (1998) Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma - a report of the Children’s Cancer Group. J Neurooncol 371135143

    Google Scholar 

  94. Matthay KK,Villablanca JG, Seeger RC et al (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341: 1165–1173

    Google Scholar 

  95. Mathew P, Ribeiro RC, Sonnichsen D et al (1994) Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol 12: 1452–1457

    PubMed  CAS  Google Scholar 

  96. Merchant RE, Ellison ED, Young HF (1990) Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. J Neurooncol 8: 173188

    Google Scholar 

  97. Middleton M (2003) Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 4: 37–44

    Google Scholar 

  98. Miettinen S, Laurikainen E, Johansson R et al (1997) Radiotherapy enhanced ototoxicity of cisplatin in children. Acta Otolaryngol [Suppl] 529:90–94

    Google Scholar 

  99. Mishima K, Johns TG, Luwor RB et al (2001) Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61:5349–5354

    Google Scholar 

  100. Mukherjee P,Das SK (1990) Antiproliferative action of retinoic acid in cultured human brain tumour cells G1-As-14(S). Cancer Lett 52: 83–80

    Article  PubMed  CAS  Google Scholar 

  101. Mulhern RK, Palmer SL, Reddick WE et al (zoo]) Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 19:472-479

    Google Scholar 

  102. Needle MN, Molloy PT, Geyer JR et al (1997) Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 29: 28–32

    Article  PubMed  CAS  Google Scholar 

  103. Neuwelt EA, Diehl JT, Vu LH et al (1981) Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 94:449–454

    Google Scholar 

  104. Neuwelt EA, Specht HD, Howieson Jet al (1983) Osmotic blood-brain barrier modification: clinical documentation by enhanced CT scanning and/or radionuclide brain scanning. Am J Roentgenol 4: 907–913

    Google Scholar 

  105. Newlands ES, Stevens MF, Wedge SR et al (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 3561

    Google Scholar 

  106. Newton HB, Page MA, Junck L et al (1989) Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol 7: 39

    Article  PubMed  CAS  Google Scholar 

  107. Newton HB, Turowski RC, Stroup TJ et al (1999) Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann Pharmacother 33: 816–832

    Google Scholar 

  108. Nicholson HS, Krailo M, Ames MM et al (1998) Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children’s Cancer Group. J Clin Oncol 16:3037–3043

    Google Scholar 

  109. Ohman L, Gedda L, Hesselager G et al (2002) A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumour Biol 23: 61–69

    Article  PubMed  Google Scholar 

  110. Ortega JA, Rivard GE, Isaacs H et al (1975) The influence of chemotherapy on the prognosis of rhabdomyosarcoma. Med Pediatr Oncol 1: 227–234

    Article  PubMed  CAS  Google Scholar 

  111. Packer RJ (2002) Radiation-induced neurocognitive decline: the risks and benefits of reducing the amount of whole-brain irradiation. Curr Neurol Neurosci Rep 2: 131–133

    Article  PubMed  Google Scholar 

  112. Packer RJ, Sutton LN, Goldwein JW et al (1991) Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 74: 433–440

    Article  PubMed  CAS  Google Scholar 

  113. Packer RJ, Sutton LN, Elterman R et al (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81: 690–698

    Google Scholar 

  114. Packer RJ, Ater J, Allen Jet al (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86: 747–754

    Article  PubMed  CAS  Google Scholar 

  115. Packer RJ, Goldwein J, Nicholson HS et al (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group study. J Clin Oncol 17: 2127–2136

    PubMed  CAS  Google Scholar 

  116. Packer RJ, Raffel C, Villablanca JG et al (2000) Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J Neurosurg 92:249–254

    Google Scholar 

  117. Paku S (1998) Current concepts of tumor-induced angiogenesis. Pathol Oncol Res 4: 62–75

    Article  PubMed  CAS  Google Scholar 

  118. Papadopoulos KP, Garvin JH, Fetell M et al (1998) High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumor in children and adults. Bone Marrow Transplant 7: 661667

    Google Scholar 

  119. Parney I, Hao C, Petruk K (2000) Glioma immunology and immunotherapy. Neurosurgery 46: 778–791

    PubMed  CAS  Google Scholar 

  120. Pegg A (1990) Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119–6129

    PubMed  CAS  Google Scholar 

  121. Pegg AE, Byers T (1992) Repair of DNA containing O’-alkylguanine. FASEB J 6: 2302–2310

    PubMed  CAS  Google Scholar 

  122. Pluda JM (1997) Tumor-associated angiogenesis: mechanisms, clinical implications, therapeutic strategies. Semin Oncol 24: 203–218

    PubMed  CAS  Google Scholar 

  123. Pollack IF, Boyett JM, Finlay J (1999) Chemotherapy for high- grade gliomas of childhood. Childs Nery Syst 15: 529–544

    Google Scholar 

  124. Prados MD, Edwards MS, Rabbit J (1997) Treatment of pediatric low grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 32: 235–241

    Article  PubMed  CAS  Google Scholar 

  125. Prados MD, Schold SC Jr, Fine HA et al (2003) A randomized, double-blind placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neurooncology 5: 96–103

    CAS  Google Scholar 

  126. Pratt WB, Ruddon RW, Ensminger WD et al (1994) The anticancer drugs. Oxford University Press, New York

    Google Scholar 

  127. Rall D, Zubrod C (1962) Mechanisms of drug absorption and excretion: passage of drugs in and out of the central nervous system. Annu Rev Pharmacol 2: 109–128

    Article  CAS  Google Scholar 

  128. Rasheed BK, Stenzel TT, McLendon RE et al (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57: 4187–4190

    PubMed  CAS  Google Scholar 

  129. Riva P, Franceschi G, Arista A et al (1997) Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 80:2733–2742

    Google Scholar 

  130. Rodts GE, Black KL (1994) Trans retinoic acid inhibits in vivo tumor growth of C6 glioma in rats: effect negatively influenced by nerve growth factor. Neurol Res 16: 184–186

    Google Scholar 

  131. Rosen G (1986) Neoadjuvant chemotherapy for osteogenic sarcoma: a model for the treatment of other highly malignant neoplasms. Rec Res Cancer Res 103a48–157

    Google Scholar 

  132. Rosenberg SA, Lotze MD, Muul ML et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889–897

    Article  PubMed  CAS  Google Scholar 

  133. Sampson JH, Archer GE, Ashley DM et al (1996) Subcutaneous vaccination with irradiated, cytokine-producing tumor cells located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA 9310399–10404

    Google Scholar 

  134. Sankhla SK, Nadkarni JS, Bhagwati SN (1995) Adoptive immunotherapy using lymphokine-activated (LAK) cells and interleukin-w for recurrent malignant primary brain tumors. J Neurooncol 27a33–140

    Google Scholar 

  135. Schinkel AH, Smit JJ, van Tellingen O et al (1994) Disruption of the Mouse mdr sa P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensitivity to drugs. Cell 77: 491–502

    Google Scholar 

  136. Sexauer CL, Khan A, Burger PC et al (1985) Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study. Cancer 56: 1497–1501

    Google Scholar 

  137. Siffert J,Allen JC (2000) Late effects of therapy of thalamic and hypothalamic tumors in childhood: vascular, neurobehavioral and neoplastic. Pediatr Neurosurg 33a05–111

    Google Scholar 

  138. Sikic BI, Fisher GA, Lum BL et al (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemotherapy Pharmacology 40 [Supp11: 13–19

    Google Scholar 

  139. Skov K, MacPhail S (1991) Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. Int J Radiat Oncol Biol 20: 221–225

    Article  CAS  Google Scholar 

  140. Smith MA, Rubinstein L, Anderson JR et al (1999) Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 17: 569–577

    Google Scholar 

  141. Sposto R, Ertel IJ, Jenkin RD et al (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children; results of a randomized trial. A report from the Children’s Cancer Study Group. J Neuroonco17a65–177

    Google Scholar 

  142. Spoudeas HA, Charmandari E, Brook CG (2003) Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Med Pediatr Oncol 40: 224–229

    Article  PubMed  CAS  Google Scholar 

  143. Stewart D (1994) A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 20:121–139

    Google Scholar 

  144. Stupp R, Dietrich PY, Ostermann Kraljevic Set al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382

    Google Scholar 

  145. Tada T, Takizawa T, Nakazato F et al (1999) Treatment of intracranial nongerminomatous germ-cell tumor by high-dose chemotherapy and autologous stem-cell rescue. J Neurooncol 44: 71–76

    Google Scholar 

  146. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM (1998) Inhibition of cell migration, spreading and focal adhesions by tumor suppressor gene PTEN. Science 280: 16141617

    Google Scholar 

  147. Taylor RE, Bailey CC, Robinson K et al (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblasotma: the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 21: 1581–1591

    Article  PubMed  CAS  Google Scholar 

  148. Trimble EL, Ungerleider RS, Abrams JA et al (1993) Neoadju- vant therapy in cancer treatment. Cancer 72:3515–3524

    Google Scholar 

  149. Valtonen S, Timonen U, Toivanen P et al (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41:44–48

    Google Scholar 

  150. Viola JJ, Martuza RL (1996) Gene therapies for glioblastomas. Bailleres Clin Neurol 5:413–424

    Google Scholar 

  151. Von Bossanyi P, Diete S, Dietzmann K et al (1997) Immunohistochemical expression of P-glycoprotein and glutathione Stransferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol (Berl) 94: 605–611

    Article  Google Scholar 

  152. Von Deimling A, Louis DN, Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15: 328–338

    Google Scholar 

  153. Walker RW, Allen JC (1988) Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 6: 62–66

    PubMed  CAS  Google Scholar 

  154. White L, Kellie S, Gray E et al (1998) Postoperative chemotherapy in children less that 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children’s Cancer Study Group. J Pediatr Hematol Oncol 20: 125–130

    Google Scholar 

  155. Wickstrom E (2001) Oligonucleotide treatment of ras induced tumors in nude mice. Mol Biotechnol 18:35–55

    Google Scholar 

  156. Wiestler O, Kleihues P, Pegg AE (1984) O°-Alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. Carcinogenesis 5: 121–124

    Article  PubMed  CAS  Google Scholar 

  157. Wilkins DE, Heller DP, Raaphorst GP (1993) Inhibition of potentially lethal damage recovery by cisplatin in a brain tumor cell line. Anticancer Res 13: 2137–2142

    Google Scholar 

  158. Young SW, Quing F, Harriman A et al (1996) Gadolinium (III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 93: 6610–6615

    Article  PubMed  CAS  Google Scholar 

  159. Yu JS, Burwick JA, Dranoff G et al (1997) Gene therapy for metastatic brain tumor by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8: 1065–1072

    Article  PubMed  CAS  Google Scholar 

  160. Yung W (1994) New approaches in brain tumor therapy using gene transfer and antisense oligonucleotides. Curr Opin Oncol 6:171–178

    Google Scholar 

  161. Yung WK, Kyritsis AP, Gleason MJ et al (1996) Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 2:1931–1935

    Google Scholar 

  162. Zeltzer PM, Boyett JM, Finlay IL et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17: 832–845

    PubMed  CAS  Google Scholar 

  163. Zwelling LA, Kohn KW (1979) Mechanism of action of cis-dichlorodiammineplatinum(lI). Cancer Treatment Rep 63: 1439–1444

    CAS  Google Scholar 

Download references

Authors
  1. A. Banerjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. K. Matthay
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Pediatric Neurosurgery, Departments of Neurological Surgery and Pediatrics, University of California, San Francisco, USA

    Nalin Gupta MD, PhD (Assistant Professor, Chief) (Assistant Professor, Chief)

  2. Division of Neuro-Oncology, Departments of Neurological Surgery and Pediatrics, University of California, San Francisco, USA

    Anuradha Banerjee MD, MPH (Assistant Professor) (Assistant Professor)

  3. Department of Radiation Oncology, University of California, San Francisco, USA

    Daphne Haas-Kogan MD (Associate Professor) (Associate Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Banerjee, A., Matthay, K.K. (2004). Chemotherapy. In: Gupta, N., Banerjee, A., Haas-Kogan, D. (eds) Pediatric CNS Tumors. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09227-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-09227-9_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-05554-6

  • Online ISBN: 978-3-662-09227-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation